Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2026 Financial Results
Business Wire•29/10/2026•07:00 ET
0
Key Highlights
- ➤Cash and equivalents $469.9 million, with expected runway into 2030
- ➤Nuzefatide pevedotin received FDA Orphan Drug Designation for pancreatic cancer
- ➤BT1702 radioligand trial initiation expected in the second half of 2027
- ➤Q3 collaboration revenue $34.1 million, up from $11.7 million year over year
- ➤Q3 net loss narrowed to $10.5 million from $59.1 million year over year
Expert Statements
Kevin Lee, CEO of Bicycle Therapeutics
“We are pleased with the continued progress made across our pipeline during the third quarter, as we advance nuzefatide pevedotin in the Phase 2 clinical trial in patients with recurrent pancreatic ductal adenocarcinoma and build our emerging pipeline of next-generation radioligands. We believe the FDA’s Orphan Drug Designation for nuzefatide in pancreatic cancer further supports our development strategy and underscores the significant unmet need in this patient population”
Kevin Lee, CEO of Bicycle Therapeutics
“We remain focused on disciplined execution across our prioritized programs and believe our growing clinical data continue to demonstrate the potential of Bicycle(®) molecules to deliver highly targeted therapies with differentiated benefit/risk profiles. We look forward to advancing our pipeline and reaching important clinical milestones for nuzefatide and initiating our first company-sponsored radioligand clinical trial for BT1702 in the second half of 2027.”
Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2026 Financial Results
Nuzefatide pevedotin granted FDA Orphan Drug Designation for the treatment of pancreatic cancer; further updates expected in 2027
Get started
Create a free account to read the full story.